Hillstream BioPharma Inc. (HILS)
Hillstream BioPharma Statistics
Share Statistics
Hillstream BioPharma has 17.6M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 17.6M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 11.46M |
| Failed to Deliver (FTD) Shares | 2.78K |
| FTD / Avg. Volume | 0.41% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -0.03 and the forward PE ratio is null. Hillstream BioPharma's PEG ratio is 0.
| PE Ratio | -0.03 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 0.03 |
| P/FCF Ratio | -0.03 |
| PEG Ratio | 0 |
Enterprise Valuation
Hillstream BioPharma has an Enterprise Value (EV) of -10.7M.
| EV / Sales | 0 |
| EV / EBITDA | 1.13 |
| EV / EBIT | 1.47 |
| EV / FCF | 1.47 |
Financial Position
The company has a current ratio of 6.03, with a Debt / Equity ratio of 0.
| Current Ratio | 6.03 |
| Quick Ratio | 6.03 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | 572.87 |
Financial Efficiency
Return on Equity is -102.06% and Return on Invested Capital is -103.55%.
| Return on Equity | -102.06% |
| Return on Assets | -85.13% |
| Return on Invested Capital | -103.55% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-9.32M |
| Employee Count | 1 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 32.6% in the last 52 weeks. The beta is 0, so Hillstream BioPharma's price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | 32.6% |
| 50-Day Moving Average | 0.22 |
| 200-Day Moving Average | 0.56 |
| Relative Strength Index (RSI) | 41.23 |
| Average Volume (20 Days) | 684.78K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -9.46M |
| Net Income | -9.32M |
| EBITDA | -9.46M |
| EBIT | -9.34M |
| Earnings Per Share (EPS) | -7.14 |
Balance Sheet
The company has 10.94M in cash and 0 in debt, giving a net cash position of 10.94M.
| Cash & Cash Equivalents | 10.94M |
| Total Debt | 0 |
| Net Cash | 10.94M |
| Retained Earnings | -24.7M |
| Total Assets | 3.17M |
| Working Capital | 1.76M |
Cash Flow
In the last 12 months, operating cash flow was -7.3M and capital expenditures 0, giving a free cash flow of -7.3M.
| Operating Cash Flow | -7.3M |
| Capital Expenditures | 0 |
| Free Cash Flow | -7.3M |
| FCF Per Share | -5.59 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
HILS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -3944.02% |
| FCF Yield | -3089.55% |
Analyst Forecast
Currently there are no analyst rating for HILS.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -14.81 |
| Piotroski F-Score | 1 |